nach oben

European Journal of Clinical Microbiology & Infectious Diseases

Erschienen in:

01.11.2007 | Concise Article

The anti-cancer effects of quinolone antibiotics?

verfasst von: M. Paul, A. Gafter-Gvili, A. Fraser, L. Leibovici

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 11/2007

Einloggen, um Zugang zu erhalten

Abstract

A previous meta-analysis showed that quinolones administered for prophylaxis of infections among cancer patients reduced all-cause mortality. We extracted from the primary trials infection-related and all-cause mortality as reported and assessed the effect of quinolones on non-infection-related mortality through meta-analysis. Among trials comparing quinolones to placebo or no treatment, a significant reduction in non-infection-related mortality was observed (relative risk 0.54, 95% confidence interval 0.32–0.93, 15 trials, 3,320 patients). This finding might represent biased attribution of deaths to infection or might be compatible with an anti-cancer effect of quinolone antibiotics. We present further analyses addressing these possibilities.

Gafter-Gvili A, Fraser A, Paul M, van de Wetering M, Kremer L, Leibovici L (2005) Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 4:CD004386PubMed

Gafter-Gvili A, Fraser A, Paul M, Leibovici L (2005) Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 142:979–995PubMed

Ramphal R (2004) Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 39(Suppl 1):S25–S31PubMedCrossRef

Gerain J, Sculier JP, Malengreaux A, Rykaert C, Themelin L (1990) Causes of deaths in an oncologic intensive care unit: a clinical and pathological study of 34 autopsies. Eur J Cancer 26:377–381PubMed

Santoso JT, Lee CM, Aronson J (2006) Discrepancy of death diagnosis in gynecology oncology. Gynecol Oncol 101:311–314PubMedCrossRef

Di Furia L, Piga A, Marmili S, Breccia R, Rubini C, Beltrami CA, Mariuzzi GM, Cellerino R (1991) The value of necropsy in oncology. Eur J Cancer 27:559–561PubMedCrossRef

Dalhoff A, Shalit I (2003) Immunomodulatory effects of quinolones. Lancet Infect Dis 3:359–371PubMedCrossRef

Dalhoff A (2005) Immunomodulatory activities of fluoroquinolones. Infection 33(Suppl 2):55–70PubMedCrossRef

Shalit I, Kletter Y, Weiss K, Gruss T, Fabian I (1997) Enhanced hematopoiesis in sublethally irradiated mice treated with various quinolones. Eur J Haematol 58:92–98PubMedCrossRef

10.

Riesbeck K, Forsgren A (1990) Selective enhancement of synthesis of interleukin-2 in lymphocytes in the presence of ciprofloxacin. Eur J Clin Microbiol Infect Dis 9:409–413PubMedCrossRef

11.

Shalit I, Kletter Y, Halperin D, Waldman D, Vasserman E, Nagler A, Fabian I (2001) Immunomodulatory effects of moxifloxacin in comparison to ciprofloxacin and G-CSF in a murine model of cyclophosphamide-induced leukopenia. Eur J Haematol 66:287–296PubMedCrossRef

12.

Brodsky AL, Minissale CJ, Melero MJ, Sanchez Avalos JC (1993) Prophylaxis with fluoroquinolones in patients with neutropenia. Medicina (B Aires) 53:401–407

13.

Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D’Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Foa R, Del Favero A (2005) Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353:977–987PubMedCrossRef

14.

Carlson JW, Fowler JM, Mitchell SK, Carson LF, Mayer AR, Copeland LJ (1997) Chemoprophylaxis with ciprofloxacin in ovarian cancer patients receiving paclitaxel: a randomized trial. Gynecol Oncol 65:325–329PubMedCrossRef

15.

Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, Stuart N, Rea D, Bower M, Fernando I, Huddart R, Gollins S, Stanley A (2005) Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 353:988–998PubMedCrossRef

16.

Guiot HF, van den Broek PJ, van der Meer JW, van Furth R (1983) Selective antimicrobial modulation of the intestinal flora of patients with acute nonlymphocytic leukemia: a double-blind, placebo-controlled study. J Infect Dis 147:615–623PubMed

17.

Karp JE, Merz WG, Hendricksen C, Laughon B, Redden T, Bamberger BJ, Bartlett JG, Saral R, Burke PJ (1987) Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 106:1–7PubMed

18.

Lalami Y, Paesmans M, Aoun M, Munoz-Bermeo R, Reuss K, Cherifi S, Alexopoulos CG, Klastersky J (2004) A prospective randomised evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia. Support Care Cancer 12:725–730PubMedCrossRef

19.

Lew MA, Kehoe K, Ritz J, Antman KH, Nadler L, Takvorian T, Mayer R, Kalish L, Finberg R (1991) Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation 51:630–636PubMedCrossRef

20.

Moreau P, Milplied N, Richard P, Bulbois CE, Richet H, Harousseau JL (1995) Prospective randomized study comparing prophylactic ciprofloxacin (C) and amoxicillin + clavulanic acid (A-CA) vs prophylactic vancomycin (V) vs non prophylactic conventional empiric antimicrobial therapy in neutropenic patients [abstract]. Bone Marrow Transplantation 15(Suppl 2):129

21.

Nenova IS, Ananostev NH, Goranov SE, Mateva NG, Haidushka IA (2001) Fluoroquinolone prophylaxis for bacterial infections in neutropenic patients with hematologic malignancies. Folia Med (Plovdiv) 43:40–45

22.

Sampi K, Maseki N, Hattori M (1992) A comparison of nystatin with norfloxacin for prevention of infection after consolidation therapy in patients with acute leukemia or autologous bone marrow transplantation: a randomized study. Gan To Kagaku Ryoho 19:823–826PubMed

23.

Schroeder M, Schadeck-Gressel C, Selbach J, Westerhausen M (1992) Antibiotic prophylaxis with gyrase inhibitors during cytostatically induced granulocytopenias in patients with solid tumors: A double-blind prospective randomized study. Onkologie 15:476–479CrossRef

24.

Talbot GH, Cassileth PA, Paradiso L, Correa-Coronas R, Bond L (1993) Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. The Enoxacin Prophylaxis Study Group. Antimicrob Agents Chemother 37:474–482PubMed

25.

Thomas X, Troncy J, Belhabri A, Thiebaut A, Bouheddou N, Michallet M, Fleurette J, Pivot C, Fiere D, Archimbaud E (2000) Effectiveness of combined vancomycin and pefloxacine in gastrointestinal decontamination for preventing infections after chemotherapy-induced bone marrow aplasia. A randomized double-blind study. Presse Med 29:1745–1751PubMed

26.

Tjan-Heijnen VC, Postmus PE, Ardizzoni A, Manegold CH, Burghouts J, van Meerbeeck J, Gans S, Mollers M, Buchholz E, Biesma B, Legrand C, Debruyne C, Giaccone G (2001) Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. Ann Oncol 12:1359–1368PubMedCrossRef

27.

Kamat AM, DeHaven JI, Lamm DL (1999) Quinolone antibiotics: a potential adjunct to intravesical chemotherapy for bladder cancer. Urology 54:56–61PubMedCrossRef

28.

Kamat AM, Lamm DL (2004) Antitumor activity of common antibiotics against superficial bladder cancer. Urology 63:457–460PubMedCrossRef

29.

Seay TM, Peretsman SJ, Dixon PS (1996) Inhibition of human transitional cell carcinoma in vitro proliferation by fluoroquinolone antibiotics. J Urol 155:757–762PubMedCrossRef

30.

Zehavi-Willner T, Shalit I (1992) The inhibitory effect of ciprofloxacin on proliferation of a murine bladder carcinoma cell line. J Antimicrob Chemother 29:323–328PubMedCrossRef

31.

Ebisuno S, Inagaki T, Kohjimoto Y, Ohkawa T (1997) The cytotoxic effect of fleroxacin and ciprofloxacin on transitional cell carcinoma in vitro. Cancer 80:2263–2267PubMedCrossRef

32.

Aranha O, Wood DP Jr, Sarkar FH (2000) Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res 6:891–900PubMed

33.

Yamakuchi M, Nakata M, Kawahara K, Kitajima I, Maruyama I (1997) New quinolones, ofloxacin and levofloxacin, inhibit telomerase activity in transitional cell carcinoma cell lines. Cancer Lett 119:213–219PubMedCrossRef

34.

Somekh E, Douer D, Shaked N, Rubinstein E (1989) In vitro effects of ciprofloxacin and pefloxacin on growth of normal human hematopoietic progenitor cells and on leukemic cell lines. J Pharmacol Exp Ther 248:415–418PubMed

35.

Thadepalli H, Salem F, Chuah SK, Gollapudi S (2005) Antitumor activity of trovafloxacin in an animal model. In Vivo 19:269–276PubMed

36.

Yamashita Y, Ashizawa T, Morimoto M, Hosomi J, Nakano H (1992) Antitumor quinolones with mammalian topoisomerase II mediated DNA cleavage activity. Cancer Res 52:2818–2822PubMed

37.

Dohden K, Kaizaki Y, Hosokawa O, Hayashi H, Hattori M (2004) Regression of rectal mucosa-associated lymphoid tissue lymphoma but persistence of Helicobacter pylori infection of gastric mucosa after administration of levofloxacin: report of a case. Dis Colon Rectum 47:1544–1546PubMed

38.

Hori K, Suguro M, Koizuka H, Sakagami T, Tomita T, Kosaka T, Fukuda Y (2004) Disappearance of rectal mucosa-associated lymphoid tissue lymphoma following antibiotic therapy. Dig Dis Sci 49:413–416PubMedCrossRef

39.

Huang D, Okada K, Komori C, Itoi E, Suzuki T (2004) Enhanced antitumor activity of ultrasonic irradiation in the presence of new quinolone antibiotics in vitro. Cancer Sci 95:845–849PubMedCrossRef

40.

Miclau T, Edin ML, Lester GE, Lindsey RW, Dahners LE (1998) Effect of ciprofloxacin on the proliferation of osteoblast-like MG-63 human osteosarcoma cells in vitro. J Orthop Res 16:509–512PubMedCrossRef

41.

Herold C, Ganslmayer M, Ocker M, Blauberger S, Zopf S, Hahn EG, Schuppan D (2003) Overadditive anti-proliferative and pro-apoptotic effects of a combination therapy on colorectal carcinoma cells. Int J Oncol 23:751–756PubMed

42.

Aranha O, Grignon R, Fernandes N, McDonnell TJ, Wood DP Jr, Sarkar FH (2003) Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis. Int J Oncol 22:787–794PubMed

Titel: The anti-cancer effects of quinolone antibiotics?
verfasst von: M. Paul
A. Gafter-Gvili
A. Fraser
L. Leibovici
Publikationsdatum: 01.11.2007
Verlag: Springer-Verlag
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 11/2007
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-007-0375-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2007

In vitro activity of temocillin against prevalent extended-spectrum beta-lactamases producing Enterobacteriaceae from Belgian intensive care units

Piperacillin-tazobactam in pediatric cancer patients younger than 25 months: a retrospective multicenter survey

Persistent parvovirus B19-induced anemia in an HIV-infected patient under HAART. Case report and review of literature

Rapid identification of pathogenic yeast isolates by real-time PCR and two-dimensional melting-point analysis

Predictability of vancomycin pharmacokinetics in neonates